Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266301 | 0.89 | ACHE (0.42) | ACHESYKPLK1HTR2AHTR2C | |
| SCHEMBL10747849 | 0.81 | PLK1 (0.36) | CTNNB1WNT3APDE4APDE4BPDE4C | |
| SCHEMBL9088450 | 0.79 | AKT1 (0.42) | CTNNB1WNT3AHTR2AHTR2CHTR2B | |
| SCHEMBL24345429 | 0.79 | CTNNB1 (0.33) | CTNNB1WNT3APDE4APDE4BPDE4C | |
| SCHEMBL20416982 | 0.78 | RAPGEF4 (0.35) | CTNNB1WNT3A | |
| SCHEMBL1620222 | 0.78 | ALDH1A1 (0.41) | CTNNB1WNT3APDE4APDE4BPDE4C | |
| SCHEMBL13092266 | 0.77 | PLK1 (0.48) | ACHESYKPLK1POLB | |
| SCHEMBL9090141 | 0.76 | HPGD (0.37) | CTNNB1WNT3APOLB | |
| SCHEMBL23195622 | 0.75 | PLK1 (0.47) | CTNNB1WNT3APLK1 | |
| SCHEMBL17348468 | 0.75 | NOTUM (0.47) | PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059153-A1 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | IC-MedTech Corp. | 2025-02-20 | — | — | US | disclosed |
| EP-4465981-A1 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | IC-Medtech Corp. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118891036-A | Bicyclic quinones, pharmaceutical compositions and therapeutic uses | IC医药科技公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2023141410-A1 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | IC-MedTech Corp. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059153-A1 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SDHA, NQO1, NDUFA7 | ACHE 328/4885CTNNB1 3160/4885WNT3A 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.